Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2016, Article ID 1654938, 8 pages
http://dx.doi.org/10.1155/2016/1654938
Review Article

The Need for Pediatric Formulations to Treat Children with HIV

1Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
2Academic Model Providing Access to Healthcare (AMPATH), Eldoret 30100, Kenya

Received 23 March 2016; Accepted 25 May 2016

Academic Editor: Charles Chiedza Maponga

Copyright © 2016 Adrienne F. Schlatter et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. UNAIDS, Gap Report, 2014, http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS_Gap_report_en.pdf.
  2. World Health Organization, Health for the World's Adolescents: A Second Chance in the Second Decade, World Health Organization, Geneva, Switzerland, 2014.
  3. World Health Organization, “Treat all people living with HIV, offer antiretrovirals as additional prevention choice for people at ‘substantial’ risk,” 2015, http://who.int/mediacentre/news/releases/2015/hiv-treat-all-recommendation/en/.
  4. A. K. Sethi, D. D. Celentano, S. J. Gange, R. D. Moore, and J. E. Gallant, “Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance,” Clinical Infectious Diseases, vol. 37, no. 8, pp. 1112–1118, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Haberer and C. Mellins, “Pediatric adherence to HIV antiretroviral therapy,” Current HIV/AIDS Reports, vol. 6, no. 4, pp. 194–200, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. R. C. Vreeman, S. E. Wiehe, E. C. Pearce, and W. M. Nyandiko, “A systematic review of pediatric adherence to antiretroviral therapy in low- and middle-income countries,” The Pediatric Infectious Disease Journal, vol. 27, no. 8, pp. 686–691, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. B. R. Phelps and N. Rakhmanina, “Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges,” Pediatric Drugs, vol. 13, no. 3, pp. 175–192, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. D. C. Watson and J. J. Farley, “Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1,” Pediatric Infectious Disease Journal, vol. 18, no. 8, pp. 682–689, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Bagenda, K. Kallander, L. Barlow-Mosha, R. Byogero, and P. Musoke, “Caregiver experiences with syrup and tablet formulations of HAART for paediatric HIV treatment in an urban clinic,” in Proceedings of the 18th International AIDS Conference (AIDS '10), Vienna, Austria, 2010.
  10. A. L. Buchanan, G. Montepiedra, P. A. Sirois et al., “Barriers to medication adherence in HIV-infected children and youth based on self- and caregiver report,” Pediatrics, vol. 129, no. 5, pp. e1244–e1251, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. D. M. Gibb, R. L. Goodall, V. Giacomet, L. McGee, A. Compagnucci, and H. Lyall, “Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial,” Pediatric Infectious Disease Journal, vol. 22, no. 1, pp. 56–62, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. M.-A. Davies, A. Boulle, T. Fakir, J. Nuttall, and B. Eley, “Adherence to antiretroviral therapy in young children in Cape Town, South Africa, measured by medication return and caregiver self-report: a prospective cohort study,” BMC Pediatrics, vol. 8, article 34, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. A. E. Horace and J. Akbarian-Tefagh, “Disguising the taste of antiretrovirals for pediatric patients infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: creative flavor compounding and techniques, part 1,” International Journal of Pharmaceutical Compounding, vol. 17, no. 5, pp. 388–391, 2013. View at Google Scholar · View at Scopus
  14. C. Reddington, J. Cohen, A. Baldillo et al., “Adherence to medication regimens among children with human immunodeficiency virus infection,” Pediatric Infectious Disease Journal, vol. 19, no. 12, pp. 1148–1153, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. World Health Organization, Consolidated ARV Guidelines, 2013, http://www.who.int/hiv/pub/guidelines/arv2013/art/artchildrenunder3/en/.
  16. A. L. Ciaranello, K. Doherty, M. Penazzato et al., “Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age,” AIDS, vol. 29, no. 10, pp. 1247–1259, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. A. J. Melvin, K. M. Mohan, L. A. Manns Arcuino, R. E. Edelstein, and L. M. Frenkel, “Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors,” The Pediatric Infectious Disease Journal, vol. 16, no. 10, pp. 968–974, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. R. B. Van Dyke, S. Lee, G. M. Johnson et al., “Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection,” Pediatrics, vol. 109, no. 4, p. e61, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. D. I. Czyzewski, R. D. Runyan, M. A. Lopez, and N. R. Calles, “Teaching and maintaining pill swallowing in HIV-infected children,” The AIDS Reader, vol. 10, no. 2, pp. 88–95, 2000. View at Google Scholar · View at Scopus
  20. S. S. Schiffman, J. Zervakis, S. Heffron, and A. E. Heald, “Effect of protease inhibitors on the sense of taste,” Nutrition, vol. 15, no. 10, pp. 767–772, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. E. G. Chadwick, J. H. Rodman, P. Britto et al., “Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age,” Pediatric Infectious Disease Journal, vol. 24, no. 9, pp. 793–800, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Giaquinto, E. Morelli, F. Fregonese et al., “Current and future antiretroviral treatment options in paediatric HIV infection,” Clinical Drug Investigation, vol. 28, no. 6, pp. 375–397, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Turkova, R. H. Webb, and H. Lyall, “When to start, what to start and other treatment controversies in pediatric HIV infection,” Pediatric Drugs, vol. 14, no. 6, pp. 361–376, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Jiménez-Montero, J. Beceiro, M. I. de José-Gómez et al., “Once-daily antiretroviral therapy in a cohort of HIV-infected children and adolescents,” The Pediatric Infectious Disease Journal, vol. 33, no. 10, pp. 1052–1054, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Bagenda, L. Barlow-Mosha, D. Bagenda, R. Sakwa, M. G. Fowler, and P. M. Musoke, “Adherence to tablet and liquid formulations of antiretroviral medication for paediatric HIV treatment at an urban clinic in Uganda,” Annals of Tropical Paediatrics, vol. 31, no. 3, pp. 235–245, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. L. N. Barlow-Mosha, D. S. Bagenda, P. K. Mudiope et al., “The long-term effectiveness of generic adult fixed-dose combination antiretroviral therapy for HIV-infected Ugandan children,” African Health Sciences, vol. 12, no. 3, pp. 249–258, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. World Health Oranization, Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access, 2010.
  28. G. Anabwani, C. Königs, C. Giaquinto et al., “Nevirapine extended-release formulation tablets in HIV-1-infected children-long-term follow-up,” Clinical Infectious Diseases, vol. 61, no. 3, pp. 476–479, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Pontali, M. Feasi, F. Toscanini et al., “Adherence to combination antiretroviral treatment in children,” HIV Clinical Trials, vol. 2, no. 6, pp. 466–473, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. B. M. Best, E. V. Capparelli, H. Diep et al., “Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children,” Journal of Acquired Immune Deficiency Syndromes, vol. 58, no. 4, pp. 385–391, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Bunupuradah, S. Wannachai, A. Chuamchaitrakool et al., “Use of taste-masking product, FLAVORx, to assist Thai children to ingest generic antiretrovirals,” AIDS Research and Therapy, vol. 3, no. 1, article 30, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. UNICEF. UNICEF: A call to action. Children: the missing face of AIDS, 2005.
  33. J. M. Duggan, B. Akpanudo, V. Shukla, G. Gutterson, L. Eitniear, and E. G. Sahloff, “Alternative antiretroviral therapy formulations for patients unable to swallow solid oral dosage forms,” American Journal of Health-System Pharmacy, vol. 72, no. 18, pp. 1555–1565, 2015. View at Publisher · View at Google Scholar
  34. D. Shingadia, R. M. Viani, R. Yogev et al., “Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus,” Pediatrics, vol. 105, no. 6, article E80, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. American Academy of Pediatrics Committee on Pediatric AIDS, Section on International Child Health, P. L. Havens, and D. M. Gibb, “Increasing antiretroviral drug access for children with HIV infection,” Pediatrics, vol. 119, no. 4, pp. 838–845, 2007. View at Google Scholar
  36. World Bank, Sustainable Energy for All (SE4ALL) Database from World Bank, Global Electrification Database. Access to electricity (% of population), 2015, http://data.worldbank.org/indicator/EG.ELC.ACCS.ZS.
  37. P. Kasirye, L. Kendall, V. Musiime et al., “Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice-daily as syrups versus scored tablets in HIV-1 infected Ugandan children,” in Program and Abstracts of the 10th International Congress on Drug Therapy in HIV Infection 2010. Paper Presented at: HIV10 Congress 2010, poster 1631077, Glasgow, UK, 2010.
  38. P. Nahirya-Ntege, A. Cook, T. Vhembo et al., “Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa,” PLoS ONE, vol. 7, no. 5, Article ID e36186, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. World Health Organization, WHO Validates Elimination of Mother-to-child Transmission of HIV and Syphilis in Cuba, World Health Organization, Geneva, Switzerland, 2015, http://www.who.int/mediacentre/news/releases/2015/mtct-hiv-cuba/en/.
  40. B. Waning, E. Diedrichsen, E. Jambert et al., “The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children,” BMC Pediatrics, vol. 10, article 74, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. World Health Organization, PMTCT Strategic Vision 2010–2015: Preventing Mother-to-Child Transmission of HIV to Reach the UNGASS and Millenium Development Goals, WHO, Geneva, Switzerland, 2010.
  42. Center for Disease Control, HIV among Pregnant Women, Infants, and Children in the United States, CDC, Atlanta, Ga, USA, 2012.
  43. S. C. E. Anyangwe and C. Mtonga, “Inequities in the global health workforce: the greatest impediment to health in Sub-Saharan Africa,” International Journal of Environmental Research and Public Health, vol. 4, no. 2, pp. 93–100, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Crisp, B. Gawanas, and I. Sharp, “Training the health workforce: scaling up, saving lives,” The Lancet, vol. 371, no. 9613, pp. 689–691, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. P. A. Revill, S. Walker, T. Mabugu et al., “Opportunities for improving the efficiency of paediatric HIV treatment programmes,” AIDS, vol. 29, no. 2, pp. 201–210, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. World Health Organization, Report of the Meeting of the Paediatric Working Group Developing an Optimized list of Paediatric ARV Formulations, World Health Organization, Geneva, Switzerland, 2011.
  47. E. D. S. Pinheiro, K. Brüning, M. F. Macedo, and A. C. Siani, “Production of antiretroviral drugs in middle- and low-income countries,” Antiviral Therapy, vol. 19, supplement 3, pp. 49–55, 2014. View at Google Scholar
  48. D. J. Ripin, D. Jamieson, A. Meyers, U. Warty, M. Dain, and C. Khamsi, “Antiretroviral procurement and supply chain management,” Antiviral Therapy, vol. 19, supplement 3, pp. 79–89, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Chang, “Addressing the drug development needs of infants and young children: DNDi's pediatric HIV program,” in Proceedings of the 19th International AIDS Conference, Washington, DC, USA, 2012.
  50. National Institutes of Health, Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R01), NIH, 2014.
  51. US President’s Emergency Plan for AIDS Relief, Accelerating Children's HIV/AIDS Treatment (ACT) Initiative, 2014, http://www.pepfar.gov/partnerships/ppp/234538.htm.
  52. F. L. Lopez, T. B. Ernest, C. Tuleu, and M. O. Gul, “Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms,” Expert Opinion on Drug Delivery, vol. 12, no. 11, pp. 1727–1740, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. V. Ivanovska, C. M. A. Rademaker, L. Van Dijk, and A. K. Mantel-Teeuwisse, “Pediatric drug formulations: a review of challenges and progress,” Pediatrics, vol. 134, no. 2, pp. 361–372, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. P. Moore, “Children are not small adults,” The Lancet, vol. 352, no. 9128, p. 630, 1998. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Walsh, A. Cram, K. Woertz et al., “Playing hide and seek with poorly tasting paediatric medicines: do not forget the excipients,” Advanced Drug Delivery Reviews, vol. 73, pp. 14–33, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Zajicek, M. J. Fossler, J. S. Barrett et al., “A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms,” AAPS Journal, vol. 15, no. 4, pp. 1072–1081, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. D. E. Bastiaans, T. R. Cressey, H. Vromans, and D. M. Burger, “The role of formulation on the pharmacokinetics of antiretroviral drugs,” Expert Opinion on Drug Metabolism and Toxicology, vol. 10, no. 7, pp. 1019–1037, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. K. Pham, D. Li, S. Guo, S. Penzak, and X. Dong, “Development and in vivo evaluation of child-friendly lopinavir/ritonavir pediatric granules utilizing novel in situ self-assembly nanoparticles,” Journal of Controlled Release, vol. 226, pp. 88–97, 2016. View at Publisher · View at Google Scholar
  59. D. A. Chiappetta, Á. M. Carcaboso, C. Bregni, M. Rubio, G. Bramuglia, and A. Sosnik, “Indinavir-loaded pH-sensitive microparticles for taste masking: toward extemporaneous pediatric anti-HIV/AIDS liquid formulations with improved patient compliance,” AAPS PharmSciTech, vol. 10, no. 1, pp. 1–6, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. D. A. Chiappetta, C. Hocht, and A. Sosnik, “A highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate pediatric management of the anti-HIV therapy,” Current HIV Research, vol. 8, no. 3, pp. 223–231, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. N. Vanprapar, T. R. Cressey, K. Chokephaibulkit et al., “A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand,” Pediatric Infectious Disease Journal, vol. 29, no. 10, pp. 940–944, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. V. Giacomet, F. Albano, F. Starace et al., “Adherence to antiretroviral therapy and its determinants in children with human immunodeficiency virus infection: a multicentre, national study,” Acta Paediatrica, vol. 92, no. 12, pp. 1398–1402, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. D. Lin, J. A. Seabrook, D. M. Matsui, S. M. King, M. J. Rieder, and Y. Finkelstein, “Palatability, adherence and prescribing patterns of antiretroviral drugs for children with human immunodeficiency virus infection in Canada,” Pharmacoepidemiology and Drug Safety, vol. 20, no. 12, pp. 1246–1252, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Martin, D. K. Elliott-DeSorbo, P. L. Wolters et al., “Patient, caregiver and regimen characteristics associated with adherence to highly active antiretroviral therapy among HIV-infected children and adolescents,” The Pediatric Infectious Disease Journal, vol. 26, no. 1, pp. 61–67, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. K. Paranthaman, N. Kumarasamy, D. Bella, and P. Webster, “Factors influencing adherence to anti-retroviral treatment in children with human immunodeficiency virus in South India—a qualitative study,” AIDS Care, vol. 21, no. 8, pp. 1025–1031, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. A. J. Prendergast, M. Penazzato, M. Cotton et al., “Treatment of young children with HIV infection: using evidence to inform policymakers,” PLoS Medicine, vol. 9, no. 7, Article ID e1001273, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. A. A. Reda and S. Biadgilign, “Determinants of adherence to antiretroviral therapy among HIV-infected patients in Africa,” AIDS Research and Treatment, vol. 2012, Article ID 574656, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Corzo-Martínez, M. Mohan, J. Dunlap, and F. Harte, “Effect of ultra-high pressure homogenization on the interaction between bovine casein micelles and ritonavir,” Pharmaceutical Research, vol. 32, no. 3, pp. 1055–1071, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. V. Musiime, Q. Fillekes, A. Kekitiinwa et al., “The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children,” Journal of Acquired Immune Deficiency Syndromes, vol. 66, no. 2, pp. 148–154, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. V. Mulenga, A. Cook, A. S. Walker et al., “Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination ‘baby pills’ in Zambia: a randomized controlled trial,” Clinical Infectious Diseases, vol. 51, no. 9, pp. 1081–1089, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Choy, M. Ortiz, and R. Malkin, “Accurate dosing of antiretrovirals at home using a foilized, polyethylene pouch to prevent the transmission of HIV from mother to child,” Medicine, vol. 94, no. 25, Article ID e1030, 2015. View at Publisher · View at Google Scholar · View at Scopus
  72. N. Bouazza, F. Foissac, F. Fauchet et al., “Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations,” Antiviral Therapy, vol. 20, no. 2, pp. 225–233, 2015. View at Publisher · View at Google Scholar · View at Scopus
  73. D. N. Nguyen and G. Van Den Mooter, “The fate of ritonavir in the presence of darunavir,” International Journal of Pharmaceutics, vol. 475, no. 1, pp. 214–226, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. Y. Padmavathi, B. M. Reddy, M. Renuka, K. Sumedha, and N. P. Reddy, “Formulation and evaluation of fixed dose combination suppositories containing stavudine, lamivudine and nevirapine for pediatric applications,” Research, vol. 7, no. 3, pp. 87–96, 2015. View at Google Scholar
  75. W. R. Spreen, D. A. Margolis, and J. C. Pottage, “Long-acting injectable antiretrovirals for HIV treatment and prevention,” Current Opinion in HIV and AIDS, vol. 8, no. 6, pp. 565–571, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. D. A. Margolis and M. Boffito, “Long-acting antiviral agents for HIV treatment,” Current Opinion in HIV and AIDS, vol. 10, no. 4, pp. 246–252, 2015. View at Publisher · View at Google Scholar · View at Scopus
  77. E. Dolgin, “Long-acting HIV drugs advanced to overcome adherence challenge,” Nature Medicine, vol. 20, no. 4, pp. 323–324, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. F. Fitzgerald, M. Penazzato, and D. Gibb, “Development of antiretroviral resistance in children with HIV in low- and middle-income countries,” The Journal of Infectious Diseases, vol. 207, no. 2, pp. S85–S92, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Boni, E. Pontali, P. De Gol, P. Pedemonte, and D. Bassetti, “Compliance to combination antiretroviral therapy in HIV-1 infected children,” International Journal of Antimicrobial Agents, vol. 16, no. 3, pp. 371–372, 2000. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Bowen, P. Palasanthiran, and A. H. Sohn, “Global challenges in the development and delivery of paediatric antiretrovirals,” Drug Discovery Today, vol. 13, no. 11-12, pp. 530–535, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. D. Van der Linden, S. Callens, B. Brichard, and R. Colebunders, “Pediatric HIV: new opportunities to treat children,” Expert Opinion on Pharmacotherapy, vol. 10, no. 11, pp. 1783–1791, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. D. P. O'Brien, D. Sauvageot, R. Zachariah, and P. Humblet, “In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy,” AIDS, vol. 20, no. 15, pp. 1955–1960, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. D. W. Hoody and C. V. Fletcher, “Pharmacology considerations for antiretroviral therapy in Human Immunodeficiency Virus (HIV)-infected children,” Seminars in Pediatric Infectious Diseases, vol. 14, no. 4, pp. 286–294, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. UNITAID, Peadiatric HIV Treatment Initiative (PHTI) to Sput Innovation and Access to Improve the Lives of Children Living with HIV, UNITAID, Geneva, Switzerland, 2014.
  85. Elizabeth Glaser Pediatric AIDS Foundation, Innovation Needed on Pediatric ARV Formulations, 2015, http://b.3cdn.net/glaser/870cabd4de542e5b94_f1m6bnuiy.pdf.
  86. J. Bermudez and E. t'Hoen, “The UNITAID patent pool initiative: bringing patents together for the common good,” The Open AIDS Journal, vol. 4, pp. 37–40, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. D. L. Birx, C. V. Chien, and T. Kalil, “Accelerating Access to Innovation and Saving Children's Lives,” White House Blog, 2014, https://blogs.state.gov/stories/2014/12/05/accelerating-access-innovation-and-saving-children-s-lives#sthash.OIQaLwu8.dpuf.
  88. A. Sosnik, K. P. Seremeta, J. C. Imperiale, and D. A. Chiappetta, “Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases,” Expert Opinion on Drug Delivery, vol. 9, no. 3, pp. 303–323, 2012. View at Publisher · View at Google Scholar · View at Scopus